Sacituzumab Govitecan: First Approval
نویسندگان
چکیده
منابع مشابه
Preclinical Study on Enhancing Sacituzumab Govitecan (immu-132) Activity in Sn-38-resistant Cancer Cells Published
Morris Plains, NJ, August 18, 2016 --Immunomedics, Inc. (Nasdaq: IMMU) today announced that adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan, the Company’s lead antibody-drug conjugate (ADC) for solid cancer therapy, increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell line. Results from this preclinical study were publ...
متن کاملEnhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
PURPOSE This study examined the delivery of SN-38 to Trop-2-expressing tumors and assessed the constitutive products in the serum, liver, and small intestine in nude mice bearing human tumor xenografts (Capan-1 or NCI-N87) given a single injection of irinotecan (40 mg/kg; ∼ 0.8 mg/mouse, containing ∼ 460 μg SN-38 equivalents) or sacituzumab govitecan (IMMU-132), an antibody-drug conjugate compo...
متن کاملFirst-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
PURPOSE Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This phase I trial evaluated this ADC as a potential therapeutic for pretreated patients with a variety of metastatic solid cancers. EXPERIMENTAL DESIGN Sacituzumab govitecan was a...
متن کاملTrop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro and in vivo studies show enhanced efficacy, while there is a gradual release of SN-38 that contributes to the overall effect. IMMU-...
متن کاملImmunomedics Reports Responses with Sacituzumab Govitecan (immu-132) in Patients with Metastatic Solid Cancers Who Failed Prior Checkpoint-inhibitor Therapy
Boston, MA, April 29, 2016 --Immunomedics, Inc. (Nasdaq: IMMU) today announced that objective durable responses have been achieved with sacituzumab govitecan, its lead antibodydrug conjugate (ADC), in a number of patients with advanced, metastatic solid cancers, after failing multiple prior therapies, some including checkpoint inhibitors (CPIs). The ADC has previously been granted Breakthrough ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drugs
سال: 2020
ISSN: 0012-6667,1179-1950
DOI: 10.1007/s40265-020-01337-5